Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 6, 2013, Pages 632-638

  Stephenson, Diane ^a   Aviles, Enrique ^a   Bain, Lisa J ^b   Brumfield, Martha ^a   Carrillo, Maria ^c   Comery, Thomas A ^d   Compton, Carolyn ^e   Corrigan, Brian ^d   Gordon, Mark Forrest ^f   Jack Jr , Clifford R ^g   Katz, Russell ^h   Logovinsky, Veronika ⁱ   Satlin, Andrew ⁱ   Marek, Ken ^j   Nicholas, Timothy ^d   Polhamus, Dan ^k   Angersbach, B Steven ^a,p   Raghavan, Nandini ^l   Romano, Gary ^l   Romero, Klaus ^a   Shaw, Leslie ^m   Woodcock, Janet ^h   Vradenburg, George ⁿ   Isaac, Maria ^o   more..

^a CRITICAL PATH INSTITUTE   (United States)

^b Independent Science Writer   (United States)

^c ALZHEIMER'S ASSOCIATION   (United States)

^d PFIZER INC   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g MAYO CLINIC   (United States)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁱ EISAI INC   (United States)

^j INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^k Metrum Research Group   (United States)

^l JOHNSON AND JOHNSON   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ USAgainst Alzheimer's   (United States)

^o EUROPEAN MEDICINES AGENCY   (United Kingdom)

^p Synergia Consulting   (United States)

more..

Author keywords

Alzheimer disease; biomarkers; disease modeling; Parkinson disease; regulatory qualification

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP;

EID: 84886797572     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/2168479013498386     Document Type: Article

References (29)

1. Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf. Accessed February 26, 2013.
2. Romero K,Corrigan B,Neville J,Kopko S,Cantillon M.Striving for an integrated drug development process for neurodegeneration: the coalition against major diseases.Neurodegen Dis Manage. 2011;1 (5): 1-7.
3. Jonsson T,Atwal JK,Steinberg S, et al.A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.Nature. 2012;488 (7409): 96-99.
4. Sproul A,Jacob S,Nestor M, et al.Development of an induced pluripotent stem cell (iPSC) Alzheimer's disease model using PSEN1 mutant fibroblasts.Alzheimers Dement. 2012;8 (4 suppl): P724.
5. Sperling R,Salloway S,Honig LS, et al.A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients who are apolipoprotein E e4 non-carriers.Eur J Neurol. 2012;19 (suppl 1): 70.
6. Landen J,Cohen S,Billing C, et al.Safety, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of Ponezumab in subjects with mild-to-moderate Alzheimer's disease.Alzheimers Dement. 2012;8 (4 suppl): P708.
7. Rogers JA,Polhamus D,Gillespie WR, et al.Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis.J Pharmacokinet Pharmacodyn. 2012;39 (5): 479-498.
8. Critical Path Institute. Alzheimer's disease Clinical Trial Simulation Tool. http://www.c-path.org/AD-clinical-trial-simulation-tool.cfm. Accessed August 5, 2013.
9. Appleyard ME,Smith AD,Wilcock GK,Esiri MM.Decreased CSF acetylcholinesterase activity in Alzheimer's disease.Lancet. 1983;2 (8347): 452.
10. Jack CR,Knopman DS,Jagust WJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.Lancet Neurol. 2010;9 (1): 119-128.
11. Bateman RJ,Xiong C,Benzinger TLS, et al.Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network.N Engl J Med. 2012;367 (9): 795-804.
12. Buchhave P,Minthon L,Zetterberg H,Wallin AK,Blennow K,Hansson O.Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.Arch Gen Psychiatry. 2012;69 (1): 98-106.
13. Forster S,Grimmer T,Miederer I, et al.Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.Biol Psychiatry. 2012;71 (9): 792-797.
14. Jack CR,Vemuri P,Wiste HJ, et al.Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.Arch Neurol. 2012;69 (7): 856-867.
15. Landau SM,Mintun MA,Joshi AD, et al.Amyloid deposition, hypometabolism, and longitudinal cognitive decline.Ann Neurol. 2012;72 (4): 578-586.
16. Hill DL,Schwarz AJ,Isaac M, et al.CAMD/EMA biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stage of Alzheimer's disease.Alzheimers Dement. In press;:.
17. European Medicines Agency. Qualification opinion of low hippocampal volume (atrophy) by MRI for use in regulatory clinical trials-in pre-dementia stage of Alzheimer's disease. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500118737&mid=WC0b01ac058009a3dc. Accessed November 21, 2012.
18. Goodsaid FM,Frueh FW,Mattes W.Strategic paths for biomarker qualification.Toxicology. 2008;245 (3): 219-223.
19. European Medicines Agency. Qualification opinion of novel methodologies in predementia stage of Alzheimer's disease: cerebrospinal fluid related biomarkers for drugs affecting amyloid burden. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500106357&mid=WC0b01ac058009a3dc. Accessed December 28, 2012.
20. European Medicines Agency. Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment, for use in regulatory clinical trials in predementia Alzheimer's disease. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125018.pdf. 2012. Accessed December 28, 2012.
21. Hendrix S,Logovinsky V,Perdomo C,Wang J,Satlin A.A new tool for optimizing responsiveness to decline in early AD [abstract OC12].J Nutr Health Aging. 2012;16 (9): 805.
22. Food and Drug Administration. Draft guidance for industry. Alzheimer's disease: developing drugs for the treatment of early stage disease. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. 2013. Accessed February 2, 2013.
23. Marek K,Seibyl J.Imaging: a molecular map for neurodegeneration.Science. 2000;289 (5478): 409-411.
24. Wu Y,Le W,Jankovic J.Preclinical biomarkers of Parkinson disease.Arch Neurol. 2011;68 (1): 22-30.
25. Postuma RB,Aarsland D,Barone P, et al.Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease.Mov Disord. 2012;27 (5): 617-626.
26. Haas BR,Stewart TH,Zhang J.Premotor biomarkers for Parkinson's disease-a promising direction of research.Transl Neurodegener. 2012;1 (1): 11.
27. Gordon M,Comery T,Grachev I, et al.The Coalition Against Major Diseases: dopamine transporter neuroimaging as an enrichment biomarker to enable Parkinson's disease clinical trials.Neurology. 2013;:.
28. Goetz CG,Fahn S,Martinez-Martin P, et al.Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan.Mov Disord. 2007;22 (1): 41-47.
29. Goetz CG,Tilley BC,Shaftman SR, et al.Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.Mov Disord. 2008;23 (15): 2129-2170.